Baxter International Inc. 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Baxter International Inc. for the period ended September 30, 2008. Baxter operates in three primary segments: BioScience, Medication Delivery, and Renal. The company is a large accelerated filer incorporated in Delaware.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2008 | Nine Months Ended Sep 30, 2008 |
|---|---|---|
| Net Sales | $3,151 million | $9,217 million |
| Net Income | $472 million | $1,445 million |
| Diluted EPS | $0.74 | $2.26 |
| Operating Cash Flow | N/A | $1,895 million |
| Cash and Equivalents | $2,191 million (Sep 30, 2008) | N/A |
| Total Debt (Short + Long Term) | $3,420 million | N/A |
| Gross Margin | 48.3% | 49.1% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 15% in the quarter and 12% year-to-date compared to 2007. Growth was driven by volume increases in BioScience (ADVATE, IGIV) and Medication Delivery, partially aided by favorable foreign currency fluctuations (6 percentage points in Q3).
- Profitability: Net income rose 19% in the quarter and 18% year-to-date. However, the Medication Delivery segment's pre-tax income dropped 48% in the quarter due to significant special charges.
- Special Charges: The company recorded $72 million in Q3 and $53 million in Q1 2008 related to COLLEAGUE infusion pump remediation. Additionally, a $31 million charge was recorded in Q3 for the discontinuation of the CLEARSHOT pre-filled syringe program.
- Debt and Liquidity: Short-term debt increased to $230 million from $45 million at year-end 2007, while long-term debt rose to $3,185 million. The company issued $500 million in senior notes in May 2008 and terminated its net investment hedge portfolio in Q3 2008.
Guidance, Outlook, and Risks
- Regulatory Matters: Baxter continues to hold shipments of COLLEAGUE infusion pumps in the U.S. pending FDA approval for recommercialization. The company is also managing a recall of heparin sodium injection products due to adverse reactions, with approximately 50 lawsuits filed.
- Legal Contingencies: Significant litigation includes patent disputes (Sevoflurane, Peritoneal Dialysis), securities class actions regarding 401(k) plans, and average wholesale price (AWP) litigation. A settlement for Medicare Part B AWP claims is pending final approval.
- Market Risks: Management notes that global financial market volatility could impact borrowing costs and access to capital. Foreign currency fluctuations remain a key variable, though the company has terminated net investment hedges.
- Capital Allocation: The company repurchased $1.52 billion of stock in the first nine months of 2008. As of September 30, $1.6 billion remained available under a March 2008 authorization.
Investor Verification Checklist
- COLLEAGUE Pump Remediation: Verify the timeline for FDA approval and the adequacy of the remaining $124 million reserve for cash costs.
- Heparin Litigation: Monitor the status of the consolidated lawsuits regarding adverse reactions to heparin products.
- Segment Performance: Assess the sustainability of BioScience growth versus the drag on Medication Delivery margins from special charges.
- Debt Structure: Review the impact of terminating net investment hedges on future earnings volatility regarding foreign currency.
- Stock Repurchases: Confirm the utilization of the remaining $1.6 billion repurchase authorization given current market conditions.